<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951573</url>
  </required_header>
  <id_info>
    <org_study_id>C-13-011</org_study_id>
    <nct_id>NCT01951573</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Daily Disposable Multifocal Contact Lens Design</brief_title>
  <official_title>Delefilcon A Multifocal Plus Power Lens Design Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate non-inferiority of a new daily disposable
      multifocal contact lens in plus powers against the commercially available AIR OPTIX® AQUA
      MULTIFOCAL (AOAMF) lens in high contrast/high illumination (HC/HI) near visual acuity (VA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High Contrast/High Illumination (HC/HI) Binocular Visual Acuity (VA) at Near</measure>
    <time_frame>Dispense (Day 1), Hour 9</time_frame>
    <description>Near VA was assessed binocularly (both eyes together) at 40 centimeters, with over-refraction (OR), if necessary, and measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HC/HI Binocular VA at Distance</measure>
    <time_frame>Dispense (Day 1), Hour 9</time_frame>
    <description>Distance VA was assessed binocularly (both eyes together) at 6 meters, with over-refraction (OR), if necessary, and measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Over-refraction (OR) Monocular at Distance</measure>
    <time_frame>Dispense (Day 1), Hour 9</time_frame>
    <description>OR (the amount of additional correction needed to improve VA) at distance (equivalent to 6 meters) was assessed monocularly (for each eye separately) in diopters (D). Both eyes contributed to the mean.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Presbyopia</condition>
  <condition>Hyperopia</condition>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>Delefilcon A MF, then AOAMF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AOAMF, then Delefilcon A MF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delefilcon A multifocal contact lenses</intervention_name>
    <description>Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use</description>
    <arm_group_label>Delefilcon A MF, then AOAMF</arm_group_label>
    <arm_group_label>AOAMF, then Delefilcon A MF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon B multifocal contact lenses</intervention_name>
    <description>Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement</description>
    <arm_group_label>Delefilcon A MF, then AOAMF</arm_group_label>
    <arm_group_label>AOAMF, then Delefilcon A MF</arm_group_label>
    <other_name>AIR OPTIX® AQUA MULTIFOCAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with normal eyes who are not using any ocular medication.

          -  Must sign the Informed Consent document.

          -  Habitual lens power within the range available for the study lenses (+1.00 to +3.50
             diopters(D)).

          -  Manifest cylinder less than or equal to 0.75D.

          -  Best corrected distance VA greater than or equal to 20/25 in each eye.

          -  Existing soft contact lens (CL) wearers who wear contact lenses in both eyes at least
             5 days per week.

          -  Presbyopic with a spectacle addition (ADD) &gt;0.50D and &lt;2.75D.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Any ocular disease, inflammation, or abnormality that contraindicates CL wear.

          -  Any use of systemic or ocular medications for which CL wear could be contraindicated.

          -  History of herpetic keratitis.

          -  History of refractive surgery or irregular cornea.

          -  A clinically significant dry eye that precludes CL wear.

          -  Participation of the subject in a clinical study (including CL or CL care product)
             within the previous 30 days.

          -  Monocular (only 1 eye with functional vision).

          -  History of intolerance or hypersensitivity to any component of the test articles.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Nick, Dipl. Ing.</last_name>
    <role>Study Director</role>
    <affiliation>CIBA VISION GmbH</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <results_first_submitted>November 24, 2014</results_first_submitted>
  <results_first_submitted_qc>November 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2014</results_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contact lenses</keyword>
  <keyword>multifocal</keyword>
  <keyword>daily disposable</keyword>
  <keyword>silicone hydrogel</keyword>
  <keyword>presbyopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 1 study center located in the US.</recruitment_details>
      <pre_assignment_details>Of the 36 enrolled, 2 subjects were exited as screen failures prior to randomization. This reporting group includes all randomized subjects (34).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Delefilcon A MF, Then AOAMF</title>
          <description>Each product worn bilaterally (ie, in both eyes), as randomized, for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.</description>
        </group>
        <group group_id="P2">
          <title>AOAMF, Then Delefilcon A MF</title>
          <description>Each product worn bilaterally (ie, in both eyes), as randomized, for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, First 9 Hours of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2, Second 9 Hours of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all subjects/eyes exposed to any Investigational Product (IP) evaluated in this study.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Delefilcon A MF and AOAMF contact lenses worn during Period 1 and Period 2 in a crossover assignment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>High Contrast/High Illumination (HC/HI) Binocular Visual Acuity (VA) at Near</title>
        <description>Near VA was assessed binocularly (both eyes together) at 40 centimeters, with over-refraction (OR), if necessary, and measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.</description>
        <time_frame>Dispense (Day 1), Hour 9</time_frame>
        <population>This analysis population includes all randomized subjects excluding those who met any of the specified deviation criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Delefilcon A MF</title>
            <description>Contact lenses worn during Period 1 or Period 2 for 9-12 hours</description>
          </group>
          <group group_id="O2">
            <title>AOAMF</title>
            <description>Contact lenses worn during Period 1 or Period 2 for 9-12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>High Contrast/High Illumination (HC/HI) Binocular Visual Acuity (VA) at Near</title>
          <description>Near VA was assessed binocularly (both eyes together) at 40 centimeters, with over-refraction (OR), if necessary, and measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.</description>
          <population>This analysis population includes all randomized subjects excluding those who met any of the specified deviation criteria.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dispense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.09"/>
                    <measurement group_id="O2" value="0.12" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.09"/>
                    <measurement group_id="O2" value="0.09" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HC/HI Binocular VA at Distance</title>
        <description>Distance VA was assessed binocularly (both eyes together) at 6 meters, with over-refraction (OR), if necessary, and measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.</description>
        <time_frame>Dispense (Day 1), Hour 9</time_frame>
        <population>This analysis population includes all randomized subjects excluding those who met any of the specified deviation criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Delefilcon A MF</title>
            <description>Contact lenses worn during Period 1 or Period 2 for 9-12 hours</description>
          </group>
          <group group_id="O2">
            <title>AOAMF</title>
            <description>Contact lenses worn during Period 1 or Period 2 for 9-12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>HC/HI Binocular VA at Distance</title>
          <description>Distance VA was assessed binocularly (both eyes together) at 6 meters, with over-refraction (OR), if necessary, and measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.</description>
          <population>This analysis population includes all randomized subjects excluding those who met any of the specified deviation criteria.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dispense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.06"/>
                    <measurement group_id="O2" value="-0.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.07"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Over-refraction (OR) Monocular at Distance</title>
        <description>OR (the amount of additional correction needed to improve VA) at distance (equivalent to 6 meters) was assessed monocularly (for each eye separately) in diopters (D). Both eyes contributed to the mean.</description>
        <time_frame>Dispense (Day 1), Hour 9</time_frame>
        <population>This analysis population includes all randomized subjects excluding those who met any of the specified deviation criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Delefilcon A MF</title>
            <description>Contact lenses worn during Period 1 or Period 2 for 9-12 hours</description>
          </group>
          <group group_id="O2">
            <title>AOAMF</title>
            <description>Contact lenses worn during Period 1 or Period 2 for 9-12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Over-refraction (OR) Monocular at Distance</title>
          <description>OR (the amount of additional correction needed to improve VA) at distance (equivalent to 6 meters) was assessed monocularly (for each eye separately) in diopters (D). Both eyes contributed to the mean.</description>
          <population>This analysis population includes all randomized subjects excluding those who met any of the specified deviation criteria.</population>
          <units>Diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dispense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.16"/>
                    <measurement group_id="O2" value="0.09" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from 04 Oct 2013 to 12 Nov 2013. This analysis group includes all subjects/eyes exposed to any Investigational Product (IP) evaluated in this study.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users, or other persons, whether or not related to the investigational medical device.</desc>
      <group_list>
        <group group_id="E1">
          <title>Delefilcon A MF</title>
          <description>Contact lenses worn during Period 1 or Period 2 for 9-12 hours</description>
        </group>
        <group group_id="E2">
          <title>AOAMF</title>
          <description>Contact lenses worn during Period 1 or Period 2 for 9-12 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Fahmy, Head, Clinical Development, Vision Care</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

